Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zalfermin and Semaglutide Co-formulation
NCT05766709Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nn9500 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the concentration-time curve during a dosing interval at steady state and Maximum concentration at steady state. Started Mar 2023; status: completed.
02
Drugs
nn9500
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05766709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766709.